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Towards personalized chemotherapy of acute lymphoblastic 
leukemia
Aleš Hnízda and Tai Yang
Thiopurines, including mercaptopurine and 
6-thioguanine, are chemotherapeutics commonly used 
for treatment of acute lymphoblastic leukemia (ALL). 
Due to genetic instability of leukemia cells, efficiency 
of thiopurine treatment decreases over time that can lead 
to relapse of the disease. Among others, relapse-specific 
mutations in PRPS1 and NT5C2 were identified as 
important drivers for chemoresistant ALL [1, 2]. These 
genes are responsible for maintaining homeostasis of 
purine metabolism and are essential for conversion of 
thiopurines to pharmacologically active species. Recent 
studies showed that mutations in both genes act through 
a shared molecular mechanism, which opens new 
opportunities for targeted antileukemic therapy.
Biochemical examinations revealed that missense 
mutations in PRPS1 and NT5C2 cause misregulation 
of respective enzymes leading to their constitutive 
hyperactivity [1, 3]. PRPS1 mutants have impaired 
responsivity for allosteric inhibition via end-products of 
the purine biosynthetic pathway (GDP or ADP), while 
NT5C2 variants are constitutively active without a need for 
activating compounds such as ATP. Structurally, mutations 
in both PRPS1 and NT5C2 affect oligomerization 
interfaces, demonstrating their importance in regulatory 
movements of the proteins. Since the mutations in 
NT5C2 are heterozygous, enzymes are assembled into 
heteromeric complexes containing both wild-type and 
mutant subunits [4]. Notably, the intersubunit motions 
stimulate even the wild-type polypeptide showing that the 
heteromeric proteins have distinct properties from their 
individual components. These finding highlights protein 
complexes of variable composition as relevant drug 
targets for individualized therapy. However, structural 
studies of such mixtures are extremely challenging as 
traditional techniques (X-ray crystallography and NMR 
spectroscopy) usually require homogenous samples. 
Current obstacles might be overcome by a rapid progress 
in single-particle cryo-EM that enables 3-D classification 
to identify different protein conformations. This approach 
represents an important direction in structure-based drug 
discovery with respect to patient genotype. 
 To explore therapeutic approaches alternative to 
direct inhibition of the hyperactive variants, previous 
works have focused on the metabolic changes caused 
by PRPS1 and NT5C2 mutations [1, 5]. Hyperactive 
variants in both PRPS1 or NT5C2 lead to overproduction 
of purines and their increased secretion to extracellular 
space which blocks cellular transport of thiopurines 
and their metabolic activation via hypoxanthin-
guanin phophoribosyltransferase (HGPRT; Figure 1). 
Misregulation of the entire purine metabolism confers 
chemoresistance of leukemia cells toward thiopurines; 
however, it also decreases their fitness under normal 
conditions. This makes the cells more sensitive to 
pharmacological modulation of the purine metabolic 
pathway, as has been demonstrated by selective 
cytotoxicity of IMPDH inhibitors in leukemic cells 
carrying NT5C2 mutations [5]. In principle, additional 
enzymes in purine metabolism could be suitable targets 
in chemoresistant ALL. For instance, inhibitors against 
tri-functional GART (a core enzyme of de novo purine 
synthesis) or purine nucleoside phosphorylase (an enzyme 
upstream of NT5C2) have been clinically tested for 
various diseases that can be evaluated in a relapsed ALL 
context.
An attractive direction for future studies might be 
the targeting of purinosome, a metabolon composed of 
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Figure 1: Molecular mechanism of chemoresistant 
acute lymphoblastic leukemia due to activating 
mutations in PRPS1 and NT5C2. Mutations (highlighted 
as red spheres) are distributed at oligomeric interfaces; each 
subunit in the protein complexes is depicted in different colour. 
Hyperactivation of both enzymes causes purine overproduction 
that suppresses transport and intracellular metabolism of 
thiopurine analogs.
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enzymes from the purine de novo synthesis. Interestingly, 
purinosome formation is affected in various disorders of 
purine metabolism, including inherited defects of purine 
de novo synthesis and Lesch-Nyhan syndrome (HGPRT 
deficiency) [6, 7]. Purinosome assembly and its subcellular 
localization are regulated via multiple mechanisms such as 
cell cycle-dependent activity of casein kinase 2 and mTOR 
signalling [8]. It is tempting to speculate that modulation 
of purinosome assembly might provide novel opportunity 
for targeted anticancer therapies.
In summary, studies on PRPS1 and NT5C2 
in chemoresistant leukemia elucidated a complex 
regulatory network in the purine metabolic pathway. In 
addition, multiple novel mechanisms have been recently 
described in distinct pathological states. For instance, 
PRPS1 is also stimulated by excessive phosphorylation 
at oligomerization areas in hepatocarcinoma [9]. Taken 
together, emerging mechanisms might be exploited for 
development of individualized treatment depending on 
specific diagnosis and genotype of patients.
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